Valeant (VRX) Wellbutrin XL Pricing Strategy is Unsustainable - Wells Fargo's Maris

October 17, 2016 1:48 PM EDT
Get Alerts VRX Hot Sheet
Price: $22.05 +2.13%

Rating Summary:
    12 Buy, 11 Hold, 3 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 23 | New: 30
Trade VRX Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Wells Fargo analyst David Maris said Valeant Pharmaceuticals (NYSE: VRX) Wellbutrin XL distribution is unclear and more importantly, its pricing strategy is unsustainable.

Maris commented, "How does Wellbutrin XL still show growth when it went generic in 2006 and currently has ten generic competitors, especially when prescription trends have shown a dramatic and steady decline (total monthly prescriptions have fallen from approximately 30,000 per month two years ago to approximately 16,000 in July 2016). Traditionally, brands facing this type of generic competition see erosion in the 90% range. A January 2016 Bloomberg article discussed this subject and raised the possibility that privately held Direct Success, Valeant’s specialty distributor partner for Wellbutrin XL, might hold the key. We decided to look into this further given the importance of Wellbutrin XL to Valeant’s sales base (it is the #2 product). As a result of our review, we conclude that the Wellbutrin XL distribution is unclear and more importantly, its pricing strategy is unsustainable. In response to our questions Valeant indicated that Direct Success represents less than 5% of Wellbutrin XL sales, but Valeant could not confirm this holds true for Direct Success and all of Direct Success affiliated pharmacies. We are lowering our Wellbutrin XL sales forecasts, as detailed within. Valeant has recently informed us that it is in the process of ending its relationship with Direct Success."

Underperform and $17-$22 valuation range.

For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.

Shares of Valeant Pharmaceuticals closed at $22.18 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA, Hot Comments, Short Sales

Related Entities

Wells Fargo, David Maris

Add Your Comment